Efficacy and safety of single-agent zandelisib administered by intermittent dosing in patients with relapsed or refractory (R/R) follicular lymphoma (FL): final results of the Tidal Phase 2 Study
Zelenetz, A. D. Jurczak, W. Ribrag, V. Collins, G. P. Bishton, M. Jimenez, J. L. Dholaria, B. Mengarelli, A. Phillips, T. J.
Zelenetz, A. D.
Jurczak, W.
Ribrag, V.
Collins, G. P.
Bishton, M.
Jimenez, J. L.
Dholaria, B.
Mengarelli, A.
Phillips, T. J.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Zelenetz AD, Jurczak W, Ribrag V, Linton KM, Collins GP, Bishton M, et al. Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study. Blood. 2022 Nov;140:3595-7. PubMed PMID: WOS:000893223203281.